Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

121. [Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. (Abstract)

[Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. The present research paper aims at assessing the effectiveness of a psychoeducational intervention in relatives' groups of patients with schizophrenia or schizoaffective disorder. It examines the possible influence of the intervention on family members as well as on the course of the patient illness. Of a total of 131 relatives, 83 consisted the experimental group and 48 the control group

2015 Psychiatrike = Psychiatriki

122. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

]. 2006 Feb 2 [cited 2010 Jun 25];354(5):472-82. Available from: Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005 Jan;66(1):63-72. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive (...) ):274-85. Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006 Aug;21(6):393-8. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52-63. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. Prolactin levels in schizophrenia

2015 CADTH - Health Technology Assessment

123. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Full Text available with Trip Pro

Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Cognitive behavioural therapy for people with schizophrenia is a psychotherapeutic approach that establishes links between thoughts, emotions and behaviours and challenges dysfunctional thoughts. There is some evidence to suggest that cognitive behavioural therapy for people with psychosis (CBTp) might be an effective treatment for people with schizophrenia. There are however, limitations in its provision due (...) to available resource and training issues. One way to tackle this issue might be to offer a brief version of CBTp.To review the effects of brief CBTp (6 to 10 regular sessions given in less than 4 months and using a manual) for people with schizophrenia compared with standard CBTp (12 to 20 regular sessions given in 4 to 6 months and using a manual).We searched the Cochrane Schizophrenia Group's Trials Register (August 21, 2013 and August 26, 2015) which is based on regular searches of CINAHL, BIOSIS, AMED

2015 Cochrane

124. Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses

Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses | CADTH.ca Find the information you need Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Published on: December 15, 2011 Project Number: HO503 Product Line: Result type: Report The Canadian Agency for Drugs and Technologies in Health (...) (CADTH) has undertaken an optimal use project to assess the clinical and economic impact of using atypical antipsychotic combination therapy, as well as high-dosing treatment strategies, in adolescents and adults with schizophrenia. The current project has several key components: Appraise the clinical and cost-effectiveness of combination and high-dose therapy with atypical antipsychotic agents for the treatment of schizophrenia Develop optimal use recommendations or advice Identify gaps in current

2015 CADTH - Optimal Use

125. Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. Full Text available with Trip Pro

Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. Schizophrenia is a psychiatric disorder which involves distortions in thought and perception, blunted affect, and behavioural disturbances. The longer psychosis goes unnoticed and untreated, the more severe the repercussions for relapse and recovery. There is some evidence that early intervention services can help, and diagnostic techniques that could contribute to early (...) an individual will progress on to developing schizophrenia as opposed to other types of psychosis.To determine whether VBM applied to the brain can be used to differentiate schizophrenia from other types of psychosis in participants who have received a clinical diagnosis of first episode psychosis.In December 2013, we updated a previous search (May 2012) of MEDLINE, EMBASE, and PsycInfo using OvidSP.We included retrospective and prospective studies that consecutively or randomly selected adolescent

2015 Cochrane

126. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

]. 2006 Feb 2 [cited 2010 Jun 25];354(5):472-82. Available from: Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005 Jan;66(1):63-72. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive (...) ):274-85. Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006 Aug;21(6):393-8. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52-63. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. Prolactin levels in schizophrenia

2015 CADTH - Health Technology Assessment

127. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie (...) in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Article Text Causes and risk factors Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D 2/3 receptor occupancy following risperidone and olanzapine dose reduction Hiroyoshi Takeuchi , Gary Remington Statistics from Altmetric.com ABSTRACT FROM: Graff-Guerrero A, Rajji TK, Mulsant BH, et al . Evaluation of antipsychotic

2015 Evidence-Based Mental Health

128. Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia

Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Article Text

2015 Evidence-Based Mental Health

129. Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia

Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Article Text Psychological interventions Sustained

2015 Evidence-Based Mental Health

130. Helping people with schizophrenia to quit smoking Full Text available with Trip Pro

). On the other hand, this review noted that there were no significant differences in schizophrenic or depressive symptoms between bupropion and placebo. In the included trials, as reported in the literature for bupropion in general, the drug was associated with insomnia, restlessness and dry mouth among others. You conclude that there is moderate quality evidence that bupropion would bring an important yet small benefit for people with schizophrenia who smoke but who would like to quit smoking. After some (...) Helping people with schizophrenia to quit smoking Helping people with schizophrenia to quit smoking | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search

2015 Evidence-Based Mental Health

131. Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes

in schizophrenic mothers confirm previous findings in the context of newer antipsychotic drugs and treatment practices. Women with schizophrenia should be counselled about increased risks and followed by a provider specialising in high-risk pregnancies. Strategies to address modifiable risk factors during pregnancy and the perinatal period are necessary. Special attention should be given to smoking cessation and control of blood pressure. Novel findings include increased rates of thromboembolic disease (...) Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our

2015 Evidence-Based Nursing

132. Vraylar (cariprazine) - To treat schizophrenia and bipolar disorder in adults

Vraylar (cariprazine) - To treat schizophrenia and bipolar disorder in adults Vraylar (Cariprazine) U.S. Department of Health and Human Services Search FDA Submit search Vraylar (Cariprazine) Vraylar (Cariprazine) Company: Forest Laboratories, LLC Application No.: 204370 Orig1 and Orig2 Approval Date: September 17, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

133. Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia

Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia Aristada (aripiprazole lauroxil) U.S. Department of Health and Human Services Search FDA Submit search Aristada (aripiprazole lauroxil) Aristada (aripiprazole lauroxil) Company: Alkermes, Inc. Application No.: 207533 Approval Date: October 5, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

134. Metformin to reduce weight gain and metabolic disturbance in schizophrenia

Metformin to reduce weight gain and metabolic disturbance in schizophrenia Metformin to reduce weight gain and metabolic disturbance in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin to reduce weight gain and metabolic disturbance in schizophrenia Article Text Pharmacological interventions Metformin to reduce weight gain and metabolic disturbance in schizophrenia Guy Faulkner , Mark Duncan Statistics from

2015 Evidence-Based Mental Health

135. Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia

Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Article Text Causes and risk factors Environmental

2015 Evidence-Based Mental Health

136. Rexulti (brexpiprazole) - To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder

Rexulti (brexpiprazole) - To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder REXULTI (brexpiprazole) Tablets U.S. Department of Health and Human Services Search FDA Submit search REXULTI (brexpiprazole) Tablets ENTRESTO Company: Otsuka Pharmaceutical Company, Ltd. Application No.: 205422Orig1s000 and 205422Orig2s000 Approval Date: July 10, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2015 FDA - Drug Approval Package

137. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. (Abstract)

Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic drugs, however, low-potency antipsychotic drugs are sometimes perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side effects.To review the effects in clinical response of flupenthixol and low-potency (...) antipsychotics for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (July 2010).Randomised controlled trials that compared flupenthixol with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis.We extracted data independently. For continuous data, we calculated mean differences (MD) based on a random-effects model.The review currently includes one randomised trial from mainland China with 153 participants

2014 Cochrane

138. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Lurasidone (Latuda - Sunovion Pharmaceuticals (...) Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that lurasidone be listed for the management of the manifestations of schizophrenia if the following clinical criteria are met: 1. Patient has a contraindication to less expensive antipsychotic agents, or 2. Patient has failed a trial of less expensive antipsychotics because of intolerance

2014 Health Technology Assessment (HTA) Database.

139. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation CADTH. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Clinical Report. 2014 Authors' conclusions The main reason for the original CDEC recommendation of "Do Not List" was a lack of sufficient evidence to establish the comparative efficacy of lurasidone against other AAPs. In this updated review, no additional RCTs meeting the inclusion

2014 Health Technology Assessment (HTA) Database.

140. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions At the submitted price of XXXXXX, lurasidone (XXXXXX per year) is less expensive than aripiprazole ($1,509 to $1,746 per year) and ziprasidone ($1,448 per year). Therefore, lurasidone would

2014 Health Technology Assessment (HTA) Database.